COST-EFFECTIVENESS OF PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL CANCER OR HER2-NEGATIVE GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IN FRANCE

被引：0
|
作者：
Aparicio, T. [1 ]
Mackosso, C. [2 ]
Cagnan, L. [3 ]
Bensimon, L. [3 ]
Tehard, B. [4 ]
Boussahoua, M. [4 ]
Zhang, S. [5 ]
Qu, T. [6 ]
Meng, Y. [7 ]
Francois, E. [8 ]
机构：
[1] St Louis Hosp, Paris, NJ, France
[2] MSD France, Puteaux La Defense, France
[3] MSD France, Paris, France
[4] Vyoo Agcy, Paris 75, France
[5] Merck, Rahway, NJ USA
[6] Luminaty, Bethesda, MD USA
[7] Luminaty, Las Vegas, NV USA
[8] Ctr Antoine Lacassagne, Nice, France
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE284
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Y.
    Bhagia, Pooja
    Li Kan
    Adelberg, David E.
    Kui, Qin Shu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] COST-EFFECTIVENESS OF FIRST-LINE NIVOLUMAB COMBINATION THERAPY VS CHEMOTHERAPY ALONE FOR ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Ben-Umeh, K.
    Okoye, G.
    Malone, D. C.
    King, J.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S87 - S88
  • [33] Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Wen, Feng
    Wu, Qiu-Ji
    Li, Qiu
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1021 - 1030
  • [34] Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan
    Kashiwa, Munenobu
    Matsushita, Ryo
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (07) : 895 - 903
  • [35] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [36] A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Brauchli, Peter
    Klingbiel, Dirk
    Dedes, Konstantin J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
    Luo, Xianmei
    Cai, Tingting
    Wu, Jinyan
    Li, Xingyu
    Wang, Xiaofan
    Ma, Haiying
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [38] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [39] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Huang, Min
    Fasching, Peter
    Haiderali, Amin
    Pan, Wilbur
    Gray, Emma
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    [J]. IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
  • [40] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    [J]. TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
12345